TWI899057B - 接受造血幹細胞移植的患者之血液惡性腫瘤的復發抑制劑 - Google Patents

接受造血幹細胞移植的患者之血液惡性腫瘤的復發抑制劑

Info

Publication number
TWI899057B
TWI899057B TW108126590A TW108126590A TWI899057B TW I899057 B TWI899057 B TW I899057B TW 108126590 A TW108126590 A TW 108126590A TW 108126590 A TW108126590 A TW 108126590A TW I899057 B TWI899057 B TW I899057B
Authority
TW
Taiwan
Prior art keywords
benzyloxyphenylthio
chlorophenyl
propane
diol
ethyl
Prior art date
Application number
TW108126590A
Other languages
English (en)
Chinese (zh)
Other versions
TW202011948A (zh
Inventor
克勞德 科拉多
克里斯多福 布查
茱莉 瓊斯
彼德 傑格利
Original Assignee
愛爾蘭商普萊歐塞拉有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 愛爾蘭商普萊歐塞拉有限公司 filed Critical 愛爾蘭商普萊歐塞拉有限公司
Publication of TW202011948A publication Critical patent/TW202011948A/zh
Application granted granted Critical
Publication of TWI899057B publication Critical patent/TWI899057B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW108126590A 2018-07-27 2019-07-26 接受造血幹細胞移植的患者之血液惡性腫瘤的復發抑制劑 TWI899057B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2018-141411 2018-07-27
JP2018141411 2018-07-27
JP2019036598 2019-02-28
JP2019-036598 2019-02-28

Publications (2)

Publication Number Publication Date
TW202011948A TW202011948A (zh) 2020-04-01
TWI899057B true TWI899057B (zh) 2025-10-01

Family

ID=69181631

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108126590A TWI899057B (zh) 2018-07-27 2019-07-26 接受造血幹細胞移植的患者之血液惡性腫瘤的復發抑制劑

Country Status (11)

Country Link
US (1) US20210283073A1 (https=)
EP (1) EP3831370A4 (https=)
JP (1) JP7389486B2 (https=)
KR (1) KR102948053B1 (https=)
CN (2) CN112512516A (https=)
AU (1) AU2019311609B2 (https=)
BR (1) BR112021001376A2 (https=)
IL (1) IL280451B2 (https=)
MX (1) MX2021001039A (https=)
TW (1) TWI899057B (https=)
WO (1) WO2020022507A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021424131A1 (en) * 2021-01-28 2023-07-27 Priothera Limited Methods of treatment with s1p receptor modulators
EP4248958A3 (en) 2021-01-28 2024-01-03 Priothera SAS Methods of treatment with s1p receptor modulators
EP4282407A1 (en) 2022-05-27 2023-11-29 Priothera SAS Treatment of cancer with s1p receptor agonists

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080032923A1 (en) * 2004-07-16 2008-02-07 Shinji Kudou Effective Use Method Of Medicaments And Method Of Preventing Expression Of Side Effect
WO2014128611A1 (en) * 2013-02-20 2014-08-28 Novartis Ag Treatment of graft versus host disease in transplant patients
WO2017153889A1 (en) * 2016-03-08 2017-09-14 Novartis Ag Treatment of hematopoietic stem cell transplant patients

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1431275B1 (en) 2001-09-27 2010-04-07 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
MXPA04002679A (es) 2001-09-27 2004-07-30 Kyorin Seiyaku Kk Derivados de sulfuro de diarilo, sales de los mismos y agentes inmunosupresores que utilizan los mismos.
EP1806338B1 (en) 2004-10-12 2016-01-20 Kyorin Pharmaceutical Co., Ltd. Process for producing 2-amino-2-[2-[4-(3-benzyloxy-phenylthio)-2-chlorophenyl[ethyl]-1,3-propanediol hydrochloride and hydrates thereof. and intermediates the production thereof
SI1932522T1 (sl) 2005-10-07 2012-08-31 Kyorin Seiyaku Kk Terapevtsko sredstvo za jetrno bolezen, ki vsebuje 2-amino-1,3- propandiolni derivat kot aktivno sestavino
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
AU2009206733A1 (en) * 2008-01-25 2009-07-30 Arena Pharmaceuticals, Inc. Dihydro- 1H- pyrrolo [1,2-a] indol-1-yl carboxylic derivatives which act as S1P1 agonists
WO2014120949A1 (en) * 2013-01-30 2014-08-07 Memorial Sloan-Kettering Cancer Center Donor kir3dl1 and hla-b subtypes and leukemia control in hla-compatible allogenic hematopoietic stem cell transplantation
US10154989B2 (en) * 2015-09-17 2018-12-18 Emory University Methods of managing graft versus host disease (GvHD) using indole carboxyaldehydes or derivatives thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080032923A1 (en) * 2004-07-16 2008-02-07 Shinji Kudou Effective Use Method Of Medicaments And Method Of Preventing Expression Of Side Effect
WO2014128611A1 (en) * 2013-02-20 2014-08-28 Novartis Ag Treatment of graft versus host disease in transplant patients
WO2017153889A1 (en) * 2016-03-08 2017-09-14 Novartis Ag Treatment of hematopoietic stem cell transplant patients

Also Published As

Publication number Publication date
MX2021001039A (es) 2021-04-12
KR102948053B1 (ko) 2026-04-06
CN112512516A (zh) 2021-03-16
WO2020022507A1 (ja) 2020-01-30
EP3831370A4 (en) 2022-04-27
IL280451B1 (en) 2025-06-01
BR112021001376A2 (pt) 2021-04-20
US20210283073A1 (en) 2021-09-16
JP7389486B2 (ja) 2023-11-30
KR20210040954A (ko) 2021-04-14
IL280451B2 (en) 2025-10-01
CA3106608A1 (en) 2020-01-30
TW202011948A (zh) 2020-04-01
AU2019311609A1 (en) 2021-02-04
CN120284929A (zh) 2025-07-11
AU2019311609B2 (en) 2024-09-26
EP3831370A1 (en) 2021-06-09
IL280451A (en) 2021-03-25
JPWO2020022507A1 (ja) 2021-08-05

Similar Documents

Publication Publication Date Title
US9358233B2 (en) Method for treating acute myeloid leukemia
TWI899057B (zh) 接受造血幹細胞移植的患者之血液惡性腫瘤的復發抑制劑
JP7266030B2 (ja) リンパ球悪性疾患を治療するための方法
JP2021063014A (ja) 白血病治療薬
KR20230136603A (ko) S1p 수용체 조정제를 사용한 치료 방법
EP3200879B1 (en) Combination treatment of acute myeloid leukemia and myelodysplastic syndrome iii
Blumel et al. Bendamustine: a novel cytotoxic agent for hematologic malignancies.
CA3106608C (en) Preparation for inhibiting recurrence of hematological malignancy in patients who have undergone hematopoietic stem cell transplantation
WO2022074600A1 (en) Use of an erk inhibitor for the treatment of myelofibrosis
EP4225316A1 (en) Use of an erk inhibitor for the treatment of myelofibrosis
AU2017231000B2 (en) Treatment of hematopoietic stem cell transplant patients
HK40050286A (en) Agent for inhibiting recurrence of hematological malignancy in patients who have undergone hematopoietic stem cell transplantation
EA048825B1 (ru) Препарат для подавления рецидива гематологической злокачественной опухоли у пациентов, перенесших трансплантацию гемопоэтических стволовых клеток
Parmar et al. Cancer Chemotherapy: Recent Developments in Hematology Oncology
KR20250021323A (ko) 노인 환자에서 항-cd20/항-cd3 이중특이적 항체를 사용하여 치료하기 위한 투약법
WO2022226011A1 (en) Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3yl)-4-(2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
CN114450008A (zh) Mdm2抑制剂用于治疗骨髓纤维化的用途
Cunningham et al. From: The 50th Annual Meeting of the American Society of Hematology: San Francisco, CA; December 6-9, 2008